DeepMed Research

ADVERUM BIOTECHNOLOGIES INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: $150.5M

Website

Clinical Trials

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

Phase 3

Recruiting

Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Wet AMD

Interventions: Genetic: Ixo-vec
Drug: Aflibercept

First Posted Date: 2025-03-04

Last Posted Date: 2025-05-18

Lead Sponsor: Adverum Biotechnologies, Inc.

Target Recruit Count: 284

Registration Number: NCT06856577

Locations: 🇺🇸
Adverum Clinical Site 175, Santa Barbara, California, United States
🇺🇸
Adverum Clinical Site 178, Phoenix, Arizona, United States
🇺🇸
Adverum Clinical Site 159, Tucson, Arizona, United States

and more 29 locations

Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

Active, not recruiting

Conditions: Diabetic Macular Edema
Diabetic Retinopathy

Interventions: Genetic: ADVM-022

First Posted Date: 2022-11-07

Last Posted Date: 2025-04-22

Lead Sponsor: Adverum Biotechnologies, Inc.

Target Recruit Count: 22

Registration Number: NCT05607810

Locations: 🇵🇷
Adverum Clinical Site, Arecibo, Puerto Rico

Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]

Phase 2

Active, not recruiting

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Genetic: ADVM-022

First Posted Date: 2022-09-13

Last Posted Date: 2025-03-03

Lead Sponsor: Adverum Biotechnologies, Inc.

Target Recruit Count: 69

Registration Number: NCT05536973

Locations: 🇺🇸
Adverum Clinical Site 162, McAllen, Texas, United States
🇺🇸
Adverum Clinical Site 108, Bellaire, Texas, United States
🇬🇧
Adverum Clinical Site 601, Oxford, United Kingdom

and more 36 locations

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Active, not recruiting

Conditions: Wet Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration

Interventions: Biological: ADVM-022

First Posted Date: 2020-11-27

Last Posted Date: 2024-08-07

Lead Sponsor: Adverum Biotechnologies, Inc.

Target Recruit Count: 23

Registration Number: NCT04645212

Locations: 🇺🇸
Adverum Clinical Site, The Woodlands, Texas, United States

ADVM-022 Intravitreal Gene Therapy for DME

Phase 2

Completed

Conditions: Diabetic Macular Edema
Diabetic Retinopathy

Interventions: Biological: Aflibercept
Biological: 6E11 vg/eye of ADVM-022
Biological: 2E11 vg/eye of ADVM-022

First Posted Date: 2020-06-05

Last Posted Date: 2023-08-08

Lead Sponsor: Adverum Biotechnologies, Inc.

Target Recruit Count: 36

Registration Number: NCT04418427

Locations: 🇵🇷
Adverum Clinical Site, Arecibo, Puerto Rico

Long-Term Follow-up Study of ADVM-043

Completed

Conditions: Alpha-1 Antitrypsin Deficiency

Interventions: Genetic: No Intervention

First Posted Date: 2019-01-15

Last Posted Date: 2022-03-31

Lead Sponsor: Adverum Biotechnologies, Inc.

Target Recruit Count: 6

Registration Number: NCT03804021

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

ADVM-022 Intravitreal Gene Therapy for Wet AMD

Phase 1

Completed

Conditions: Wet Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration

Interventions: Biological: ADVM-022

First Posted Date: 2018-11-21

Last Posted Date: 2023-08-08

Lead Sponsor: Adverum Biotechnologies, Inc.

Target Recruit Count: 30

Registration Number: NCT03748784

Locations: 🇺🇸
Adverum Clinical Site, The Woodlands, Texas, United States

A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)

Not Applicable

Completed

Conditions: Friedreich's Ataxia

Interventions: Procedure: Cardiac magnetic resonance imaging (CMR)
Procedure: Exercise-stress test
Procedure: Echocardiography (ECHO)
Procedure: Cardiac-related blood studies

First Posted Date: 2016-07-21

Last Posted Date: 2018-12-10

Lead Sponsor: Adverum Biotechnologies, Inc.

Target Recruit Count: 40

Registration Number: NCT02840669

Locations: 🇫🇷
Hôpital Pitié-Salpêtrière, AP-HP, Paris, France

Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

Phase 1

Completed

Conditions: Alpha 1-Antitrypsin Deficiency

Interventions: Genetic: ADVM-043

First Posted Date: 2014-06-20

Last Posted Date: 2023-10-05

Lead Sponsor: Adverum Biotechnologies, Inc.

Target Recruit Count: 6

Registration Number: NCT02168686

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸
University of Florida, Gainesville, Florida, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy